Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Applied DNA Sciences (APDN) Reports In-Line Q2 EPS
May 13, 2021 4:28 PM EDTApplied DNA Sciences (NASDAQ: APDN) reported Q2 EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $2.6 million.
We are pleased to deliver a strong fiscal second quarter with year-over-year revenue growth of 384%, capping an impressive first half of the fiscal year distinguished by demand for our COVID-19 diagnostics and surveillance testing offerings (cumulatively COVID-19 testing business), said Dr. James A. Hayward, president and CEO, Applied DNA. Our strategic and operational execution across non-COVID-19 testing initiatives was also notable: we launched our first-ever clinical... More
